Presentation to be Webcast on November 7, 2016 at 1:30 P.M. MT
WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 26, 2016--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
make a presentation followed by a question and answer session with
investors at the Credit Suisse 25th Annual Healthcare
Conference on Monday, November 7 at 1:30 p.m. MT.
A live webcast and replay of the presentation will be accessible by
visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
The webcast replay will be available following the conference and will
be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on four disease
targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A inhibitors that
are members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta’s protease
inhibitors, developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie’s marketed DAA regimens for
HCV, and glecaprevir (ABT-493), Enanta’s second protease inhibitor,
which AbbVie is developing in Phase 3 studies in combination with
pibrentasvir (ABT-530), AbbVie’s NS5A inhibitor. Enanta has also
discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting
mechanism for HCV, which is now in a clinical proof-of-concept study in
HCV patients, and EDP-305, an FXR agonist product candidate for NASH,
currently in Phase 1 clinical development. Please visit www.enanta.com
for more information on our programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161026005092/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710